Investigation Report on China’s Recombinant Human Lutropin alfa Market, 2018-2022

$2,200$3,300

Clear

Description

Description
According to the WHO’s estimate, infertility affects 15% to 20% of the global population. Survey data shows that in 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. As environmental pollution intensifies and the lifestyle changes, the incidence of infertility is increasing and infertility is increasingly prevalent among Chinese young people. About 15% to 20% women of childbearing age in China are troubled by infertility. As the biggest cause of female infertility in China, follicular dysplasia syndrome resulting from endocrine dysfunction accounts for over 40% of infertility cases. In addition to reasonable adjustments to menstrual period and etiological treatment, for fertilization, it is necessary to adopt an ideal solution to promote the development and maturation of follicles in clinical treatment.
Since 2015 when the Chinese government relaxed its family planning policy, sex hormone drugs have been growing rapidly, and the infertility treatment and IVF, an assisted reproductive technology (ART), have attracted much attention. In China’s end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic Gonadotropin, and Human Lutropin alfa are taking the place of small-molecule chemicals.
Recombinant Human Lutropin alfa is a glycoprotein obtained by genetic engineering technique. It can combine with the luteinizing hormone/chorionic gonadotropin (LH/CG) receptor on the ovariole sheath (and granular layer) and the Leydig cell membrane. For women who lack luteinizing hormone and follicle-stimulating hormone (FSH) to ovulate, the use of LH can increase the level of estradiol secreted by the follicle and stimulate follicular development.
Merck Serono’s Recombinant Human Lutropin alfa (trade name: Luveris) was approved to be sold in China in 2008. In 2017, the sales value exceeded CNY 30 million. By the end of 2018, China’s Recombinant Human Lutropin alfa market is monopolized by Merck Serono. According to CRI’s analysis, multinational companies such as Merck Serono and Merck Sharp & Dohme dominate China’s fertility drug market. Meanwhile, Chinese companies such as Livzon Pharmaceutical Group Inc., GeneScience Pharmaceuticals Co., Ltd., Zhejiang Xianju Pharmaceutical Co., Ltd., Hybio Pharmaceutical Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. are also launching generic drugs. It is expected that the pattern of China’s Recombinant Human Lutropin alfa market will change in the next few years.
In 2015, the Chinese government relaxed its “family planning policy” that had been implemented for over three decades, allowing each couple to have two children. In China, about 90 million women of childbearing age are eligible to have a second child. And an estimated 30% of them have the desire. Therefore, China’s fertility drug market is promising.

Topics Covered:
– Situation of infertility in China
– Overview of China’s fertility drug market
– Analysis on the fertility drug manufacturers in China
– Major factors influencing the development of fertility drugs in China
– Forecast on China’s Recombinant Human Lutropin alfa market from 2018 to 2022

Table of Contents

Table of Contents
1 Relevant Concepts of Recombinant Human Lutropin alfa
1.1 Indications for Recombinant Human Lutropin alfa
1.2 Development of Recombinant Human Lutropin alfa in China
1.3 Governmental Approval of Recombinant Human Lutropin alfa in China

2 Sales of Recombinant Human Lutropin alfa in China, 2013-2017
2.1 Sales Value of Recombinant Human Lutropin alfa
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Lutropin alfa
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Lutropin alfa by Dosage Form in China, 2013-2017

3 Analysis on Major Recombinant Human Lutropin alfa Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Recombinant Human Lutropin alfa Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Merck Serono
3.2.1 Enterprise Profile
3.2.2 Sales of Merck Serono’s Recombinant Human Lutropin alfa in China

4 Prices of Recombinant Human Lutropin alfa in China, 2017-2018
4.1 Merck Serono (Luveris)
4.2 Prices of Other Fertility Drugs

5 Prospect of China’s Recombinant Human Lutropin alfa Market, 2018-2022
5.1 Major Factors Influencing Development of Recombinant Human Lutropin alfa in China
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Governmental Approval of Recombinant Human Lutropin alfa in China
Chart Sales Value of Recombinant Human Lutropin alfa in China, 2013-2017
Chart Sales Value of Recombinant Human Lutropin alfa in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Lutropin alfa in China, 2013-2017
Chart Sales Volume of Recombinant Human Lutropin alfa in Parts of China, 2013-2017
Chart Sales Value of Recombinant Human Lutropin alfa Injections in China, 2013-2017
Chart Sales Volume of Recombinant Human Lutropin alfa Injections in China, 2013-2017
Chart Sales Value of Merck Serono’s Recombinant Human Lutropin alfa in China, 2013-2017
Chart Sales Volume of Merck Serono’s Recombinant Human Lutropin alfa in China, 2013-2017
Chart Prices of Merck Serono’s Recombinant Human Lutropin alfa in Parts of China, 2017-2018
Chart Forecast on Sales Value of Recombinant Human Lutropin alfa in China, 2018-2022

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format